

Visegrad symposium

Under the auspices of Czech Myeloma Group

Chairmans: R. Hájek,

Visegrad Symposium is project of Czech Myeloma Group. It provides a platform for international communication in the management of patients with monoclonal gammopathies. This year, in 2020, is symposium focused on collaborative research in imunotherapy.

Wednesday 4.3.2020

Hall Rubín

**17.00 - 21.00 Roundtable - focus on collaborative research
(dinner during roundtable)**

Thursday 5.3.2020

Hall Gold

8.50 – 10.00 Visegrad Symposium

Wednesday 4.3.2020

Hall Rubín

**17.00 - 21.00 Roundtable - focus on collaborative research
(dinner during roundtable)**

17:00 – 17:30 *Roman Hájek (Ostrava)*
Wellcome reception/dinner

PART I: Real World Data

Hall Rubín

17:30 – 17:40 *Vladimír Maisnar (Hradec Králové)*
Current state of registry of monoclonal gammopathies

17:40 – 17:50 *Artur Jurczyszyn (Krakow)*
Primary refractory multiple myeloma – real-world experience in 94 cases

17.50 – 18:00 *Gábor Mikala (Budepest)*
**The unmet therapeutic need of myeloma with TP53 deletion: real world
experience of 102 patients**

PART II: Potential collaborative projects

Hall Rubín

18:00 – 18:10 *Sarah Goldman-Mazur (Krakow)*
MAF translocations in multiple myeloma.

18.10 – 18.20 *Sabina Ševčíková (Brno)*
Current status of preclinical research in Brno

18:20 – 18.30 *Michal Šimiček (Ostrava)*
Current status of preclinical research in Ostrava

Presentation from other centers welcome

PART III: Cell therapy projects and trials

Hall Rubín

- 19:00 – 19:15 *Zdeněk Kořístek (Ostrava)*
Research projects and clinical trial focused on cell therapy in Ostrava.
- 19:15 – 19:30 *Julio Rodriguez Bago (Ostrava)*
Current status of preclinical research in cell based therapy in Ostrava
- 19:30 – 19:45 *Jan Vydra (Praha)*
Current status of preclinical and clinical research in cell based therapy in ÚHKT Praha
- 19:45 – 20:00 *Petr Lesný (Praha)*
Development and challenges of ATMP/GTMP manufacturing in ÚHKT Praha
- 20:00 – 20:15 **Current status of CAR –T cell therapy in Visegrad countries (*all participants*)**
- 20:15 – 20:30 **Possibility of collaborative research in cell therapy (*all participants*)**

Others

Thursday 5.3.2020

Hall Gold

8.50 – 10.00 Visegrad Symposium

- 8.50 – 9:05 *Domikik Dytfeld (Poznan)*
Update on studies of Polish Myeloma Consortium
- 9:05 – 9:15 *Sabina Ševčíková (Brno)*
Liquid biopsies in MM
- 9:15 – 9:25 *Lubica Harvanová (Bratislava)*
Real-World Outcomes of Multiple Myeloma: Retrospective Analysis of the Registry of Monoclonal Gammopathies in Slovak republic
- 9:25 – 9:35 *Artur Jurczyszyn (Krakow)*
Early mortality in multiple myeloma–multicenter analysis in 213 polish patients
- 9:35 – 9:45 *Varga Gergely (Budapest)*
Marginal improvements in myeloma-care...can it turn into cure?
- 9:45 – 9:55 *Włodzimierz Mendrek (Gliwice)*
Allogeneic HCT for patients with mycosis fungoides/Sezary syndrome. Single center experience from Gliwice